HighTower Advisors
AKBA icon

HighTower Advisors’s Akebia Therapeutics AKBA Stock Holding History

HighTower Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,000
Closed -$2K – 2592
2020
Q3 		$2K Buy
+3,000
New +$26.3K ﹤0.01% 2500

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

HighTower Advisors's AKBA Position: Q1 2026 in Review

HighTower Advisors increased its Akebia Therapeutics (AKBA) stake by 14% in Q1 2026, buying an estimated $5.35K and bringing the position to 31,144 shares worth $43.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3718.

HighTower Advisors first reported a position in AKBA in Q2 2019 and has held it in 28 quarters since. The position peaked at $493K in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • HighTower Advisors held 31,144 shares of Akebia Therapeutics worth $43.3K as of Q1 2026.
  • HighTower Advisors bought 3,894 Akebia Therapeutics shares in Q1 2026, an estimated $5.35K.
  • Akebia Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3718 holding.
  • HighTower Advisors first reported a position in Akebia Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • HighTower Advisors's Akebia Therapeutics position peaked at $493K in Q2 2020.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.